AIN
Cure For Paralysis

Cure For Paralysis

location_on Israel

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

Matricelf develops the first autologous (self) neural implant to repair spinal cord injuries. Backed by strong preclinical data and heading toward First-in-Human trials in early 2026, a key inflection point.

Highlights

  • The 1st to develop functional neuronal tissue (Micro-Spinal Cord)
  • Autologous (self). Made from the patient own cells. No rejection.
  • 3d structure to accelerate integration.
  • Backed by KOL

Overview

Target NZ$ 5,100,000
Minimum NZ$ 40,000
Investment Raised NZ$ 1,700,000
Previous Rounds NZ$ 17,000,000
Stage Pre-Startup/R&D
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects